Conference
A RANDOMISED, OPEN-LABEL PHASE II TRIAL OF VOLASERTIB AS MONOTHERAPY AND IN COMBINATION WITH STANDARD DOSE PEMETREXED COMPARED WITH PEMETREXED MONOTHERAPY IN SECOND-LINE NON-SMALL CELL LUNG CANCER (NSCLC)
Authors
Ellis PM; Leighl N; Hirsh V; Reaume MN; Blais N; Wierzbicki R; Sadrolhefazi B; Gu Y; Liu D; Pilz K
Volume
8
Pagination
pp. S1200-S1200
Publisher
ELSEVIER SCIENCE INC
Publication Date
November 2013
Conference proceedings
JOURNAL OF THORACIC ONCOLOGY
ISSN
1556-0864